Akari Therapeutics (AKTX) Debt Ratio (2024 - 2025)
Akari Therapeutics (AKTX) reported Debt Ratio of 0.01 for Q1 2025, down 57.93% sequentially from 0.03 in Q4 2024.
Akari Therapeutics (AKTX) Debt Ratio (2024 - 2025) Analysis & Trends
Akari Therapeutics (AKTX) has 2 years of Debt Ratio data on file, last reported at 0.01 in Q1 2025.
- For the quarter ending Q1 2025, Debt Ratio changed N/A year-over-year to 0.01; the trailing twelve-month figure through Mar 2025 stood at 0.01 (changed N/A YoY), and the FY2024 full-year result was 0.03, changed N/A from the prior year.
- Debt Ratio fell to 0.01 in Q1 2025, from 0.03 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.03 in Q4 2024 to a low of 0.01 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 1.41 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.11 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 0.01 |
| Dec 31, 2024 | 0.03 |